{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:28:13Z","timestamp":1791167293094,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":359,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jcph.384","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T11:02:48Z","timestamp":1409137368000},"page":"168-178","source":"Crossref","is-referenced-by-count":37,"title":["Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects"],"prefix":"10.1002","volume":"55","author":[{"given":"Claudia","family":"Kasserra","sequence":"first","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Assaf","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangang","family":"Liu","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gondi","family":"Kumar","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Palmisano","sequence":"additional","affiliation":[{"name":"Celgene Corporation; 86 Morris Ave, Summit NJ 07901 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,7]]},"reference":[{"key":"10.1002\/jcph.384-BIB0001|jcph384-cit-0001","unstructured":"Approved Drugs Pomalidomide. U. S. Food and Drug Administration http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm339286.htm"},{"key":"10.1002\/jcph.384-BIB0002|jcph384-cit-0002","unstructured":"Committee for Medicinal Products for Human Use (CHMP) http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002682\/WC500143815.pdf"},{"key":"10.1002\/jcph.384-BIB0003|jcph384-cit-0003","unstructured":"Pomalyst\u00ae(pomalidomide) http:\/\/www.pomalyst.com\/"},{"issue":"12","key":"10.1002\/jcph.384-BIB0004|jcph384-cit-0004","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/jcph.384-BIB0005|jcph384-cit-0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","article-title":"The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions","volume":"77","author":"Lu","year":"2009","journal-title":"Miscrovasc Res"},{"issue":"1","key":"10.1002\/jcph.384-BIB0006|jcph384-cit-0006","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1002\/jcph.384-BIB0007|jcph384-cit-0007","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1002\/jcph.384-BIB0008|jcph384-cit-0008","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1002\/jcph.384-BIB0009|jcph384-cit-0009","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1002\/jcph.384-BIB0010|jcph384-cit-0010","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1002\/jcph.384-BIB0011|jcph384-cit-0011","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"issue":"2","key":"10.1002\/jcph.384-BIB0012|jcph384-cit-0012","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1002\/jcph.384-BIB0013|jcph384-cit-0013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration","volume":"71","author":"Hoffmann","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1002\/jcph.384-BIB0014|jcph384-cit-0014","unstructured":"Huang S http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4079b1_04_topic2-taba.pdf"},{"key":"10.1002\/jcph.384-BIB0015|jcph384-cit-0015","first-page":"217","volume-title":"Drug-Drug Interactions","author":"Madan","year":"2002"},{"issue":"1","key":"10.1002\/jcph.384-BIB0016|jcph384-cit-0016","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/dmd.105.007633","article-title":"Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions","volume":"34","author":"Ogilvie","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jcph.384-BIB0017|jcph384-cit-0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/abbi.1996.0294","article-title":"Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity","volume":"331","author":"Pearce","year":"1996","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"10.1002\/jcph.384-BIB0018|jcph384-cit-0018","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1023\/A:1010994022294","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential-toward a consensus","volume":"18","author":"Tucker","year":"2001","journal-title":"Pharm Res"},{"issue":"6","key":"10.1002\/jcph.384-BIB0019|jcph384-cit-0019","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jcph.384-BIB0020|jcph384-cit-0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2125.2009.03457.x","article-title":"The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole","volume":"68","author":"Kovarik","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1002\/jcph.384-BIB0021|jcph384-cit-0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-199427030-00002","article-title":"Clinical pharmacokinetics of fluvoxamine","volume":"27","author":"Perucca","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1002\/jcph.384-BIB0022|jcph384-cit-0022","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":"Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jcph.384-BIB0023|jcph384-cit-0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jcph.384-BIB0024|jcph384-cit-0024","unstructured":"Clinical Pharmacology Review: Pomalidomide http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204026Orig1s000ClinPharmR.pdf"},{"key":"10.1002\/jcph.384-BIB0025|jcph384-cit-0025","unstructured":"Committee for Medicinal Products for Human Use (CHMP) Guideline on the Investigation of Drug Interactions. European Medicines Agency http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf"},{"key":"10.1002\/jcph.384-BIB0026|jcph384-cit-0026","unstructured":"Guidance for Industry http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf"},{"issue":"1","key":"10.1002\/jcph.384-BIB0027|jcph384-cit-0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1002\/jcph.384-BIB0028|jcph384-cit-0028","doi-asserted-by":"crossref","DOI":"10.1002\/9783527630905","volume-title":"Metabolism of drugs and other xenobiotics","author":"Anzenbacher","year":"2012"},{"issue":"3","key":"10.1002\/jcph.384-BIB0029|jcph384-cit-0029","first-page":"307","article-title":"Cytochrome P450 polymorphism - molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs","volume":"65","author":"Tomaszewski","year":"2008","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"10.1002\/jcph.384-BIB0030|jcph384-cit-0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/tx4004215","article-title":"Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide","volume":"27","author":"Chowdhury","year":"2014","journal-title":"Chem Res Toxicol"},{"issue":"11","key":"10.1002\/jcph.384-BIB0031|jcph384-cit-0031","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1002\/jcph.384-BIB0032|jcph384-cit-0032","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1002\/jcph.384-BIB0033|jcph384-cit-0033","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1002\/jcph.384-BIB0034|jcph384-cit-0034","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1002\/jcph.384-BIB0035|jcph384-cit-0035","unstructured":"Drug Interaction Studies - Study Design Data Analysis Implications for Dosing and Labeling Recommendations http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.384","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T23:39:16Z","timestamp":1717285156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.384"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2014,9,7]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.384","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,7]]}}}